发明名称 |
Glypican-3 (GPC3)-derived tumor rejection antigenic peptides useful for HLA-A2-positive patients and pharmaceutical comprising the same |
摘要 |
It is an object of the present invention to identify a glypican-3-derived peptide which can bind to HLA-A2 and activate human killer T cells, so as to provide a means for carrying out an immunotherapy which is able to target approximately 40% of Japanese patients suffering from several types of cancers, which express GPC3 at a high level. The present invention provides a peptide of any of the following (A) or (B): (A) a peptide, which has the amino acid sequence as shown in any one of SEQ ID NOS: 1 to 3; or (B) a peptide, which has an amino acid sequence comprising a substitution or addition of one or two amino acids with respect to the amino acid sequence as shown in any one of SEQ ID NOS: 1 to 3, and which has ability to induce killer T cells.
|
申请公布号 |
US8535942(B2) |
申请公布日期 |
2013.09.17 |
申请号 |
US201113242019 |
申请日期 |
2011.09.23 |
申请人 |
NISHIMURA YASUHARU;NAKATSURA TETSUYA;KOMORI HIROYUKI;ONCOTHERAPY SCIENCE, INC. |
发明人 |
NISHIMURA YASUHARU;NAKATSURA TETSUYA;KOMORI HIROYUKI |
分类号 |
C12N5/00;A61K39/38;A61K39/385;C12N5/02 |
主分类号 |
C12N5/00 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|